Birgit C. Schultes

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

Nathaniel Washburn, Inessa Schwab, Daniel Ortiz et al. · Proceedings of the National Academy of Sciences · 2015 · 223 citations · Full text

Intravenous Immunoglobulin, Immunology, Therapeutics +21

Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer

Jonathan S. Berek, Peyton T. Taylor, Alan N. Gordon et al. · Journal of Clinical Oncology · 2004 · 196 citations · Full text

M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis

He Zhou, Sucharita Roy, Edward Cochran et al. · PLoS ONE · 2011 · 176 citations · Full text

Immunology, Tumor Progression, Pathology +19

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

Jonathan S. Berek, Peyton T. Taylor, William P. McGuire et al. · Journal of Clinical Oncology · 2008 · 170 citations

Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo

A.A. Noujaim, Birgit C. Schultes, Richard P. Baum et al. · Cancer Biotherapy and Radiopharmaceuticals · 2001 · 110 citations

Immunocytochemical Technique, T Cell Responses, Immunology +24